Polymer nanotherapeutics: A promising approach toward microglial inhibition in neurodegenerative diseases
Medicinal Research Reviews · 2024
DOI: 10.1002/med.22064 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2024. Verfasst von Sanaz Keshavarz Shahbaz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cellular and Molecular Research Center, Research Institute for prevention of Non-Communicable Disease, Qazvin University of Medical Sciences, Qazvin,…. Hauptthemen laut MEDLINE: Microglia, Neurodegenerative Diseases, Nanoparticles, Polymers. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 222 Literaturangaben.
Abstract (Originalsprache)
Nanoparticles (NPs) that target multiple transport mechanisms facilitate targeted delivery of active therapeutic agents to the central nervous system (CNS) and improve therapeutic transport and efficacy across the blood‐brain barrier (BBB). CNS nanotherapeutics mostly target neurons and endothelial cells, however, microglial immune cells are the first line of defense against neuronal damage and brain infections. Through triggering release of inflammatory cytokines, chemokines and proteases, microglia can however precipitate neurological damage—a significant factor in neurodegenerative diseases. Thus, microglial inhibitory agents are attracting much attention among those researching and developing novel treatments for neurodegenerative disorders. The most established inhibitors of microglia investigated to date are resveratrol, curcumin, quercetin, and minocycline. Thus, there is great interest in developing novel agents that can bypass or easily cross the BBB. One such approach is the use of modified‐nanocarriers as, or for, delivery of, therapeutic agents to the brain and wider CNS. For microglial inhibition, polymeric NPs are the preferred vehicles for choice. Here, we summarize the immunologic and neuroinflammatory role of microglia, established microglia inhibitor agents, challenges of CNS drug delivery, and the nanotherapeutics explored for microglia inhibition to date. We also discuss applications of the currently considered “most useful” polymeric NPs for microglial‐inhibitor drug delivery in CNS‐related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cellular and Molecular Research Center, Research Institute for prevention of Non-Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran.
- USERN Office, Qazvin University of Medical Science, Qazvin, Iran.
- Department of Neurosurgery, University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
- Department of Pharmacology, Faculty of Medicine, Qazvin University of Medical Science, Qazvin, Iran.
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
ORCID-Profile: Sanaz Keshavarz Shahbaz, Prashant Kesharwani, Amirhossein Sahebkar
Zitieren
APA
Keshavarz Shahbaz, S., Koushki, K., Keshavarz Hedayati, S., McCloskey, A. P., Kesharwani, P., Naderi, Y., & Sahebkar, A. (2024). Polymer nanotherapeutics: A promising approach toward microglial inhibition in neurodegenerative diseases. Medicinal Research Reviews. https://doi.org/10.1002/med.22064
Vancouver
Keshavarz Shahbaz S, Koushki K, Keshavarz Hedayati S, McCloskey AP, Kesharwani P, Naderi Y, et al. Polymer nanotherapeutics: A promising approach toward microglial inhibition in neurodegenerative diseases. Medicinal Research Reviews. 2024. doi:10.1002/med.22064
BibTeX
@article{KeshavarzShahbaz2024,
author = {Keshavarz Shahbaz, Sanaz and Koushki, Khadije and Keshavarz Hedayati, Samaneh and McCloskey, Alice P and Kesharwani, Prashant and Naderi, Yazdan and Sahebkar, Amirhossein},
title = {Polymer nanotherapeutics: A promising approach toward microglial inhibition in neurodegenerative diseases},
journal = {Medicinal Research Reviews},
year = {2024},
doi = {10.1002/med.22064}
}
EUVIMED